Study wrapper · #945
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
Heerspink HJL, van Raalte DH, Bjornstad P, et al. Nephrology, dialysis, transplantation. 2026.
DOI: 10.1093/ndt/gfaf230PubMed: 41160422
Editor's note
This paper reports the design and baseline characteristics of an ongoing mechanistic trial rather than any results. It establishes how retatrutide's effects on measured glomerular filtration rate and kidney structure will be evaluated, with outcomes still pending. Worth flagging as a trial to watch, with no efficacy data yet available.
Plain-language abstract
A design paper describing the rationale and baseline characteristics of the TRANSCEND-CKD Phase 2b trial, which is studying retatrutide's effects on kidney function in adults with overweight or obesity and chronic kidney disease.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026